A Peptide Therapeutic Drug Discovery Consulting Company

Our Company

Ferdia Therapeutics is a San Diego-based, privately held biotechnology consulting LLC specializing in peptide drug discovery and development, with particular expertise in the design and optimization of long-acting peptide therapeutics.

We provide end-to-end scientific and strategic consulting services to biotechnology and pharmaceutical companies, supporting programs from early discovery through preclinical evaluation and development.

Our Services

Peptide Candidate Discovery

Peptide Medicinal Chemistry & Program Support

We help clients identify, evaluate, and advance novel peptide candidates with improved potency, solubility, stability, and pharmacokinetic properties.

Our support spans early discovery through preclinical development, with a focus on identifying promising candidates and accelerating their progression toward therapeutic applications.

Peptide Medicinal Chemistry & Program Support

We provide expert medicinal chemistry guidance and strategic program support to optimize peptide candidates and advance discovery programs.

Our capabilities include:

Structure–activity relationship (SAR) analysis
Half-life extension strategies
Pharmacokinetic optimization
Improvements in potency, solubility, and stability
Peptide ligand design and optimization

We deliver practical, science-driven solutions tailored to each client's therapeutic objectives, helping accelerate the discovery and development of differentiated peptide therapeutics.

Screening Strategies & Hit Optimization

Peptide Medicinal Chemistry & Program Support

Peptide-Based Radiotherapeutics Consulting

We provide screening strategy and hit identification consulting, including coordination with external partners specializing in mRNA display, phage display, and DNA-encoded library (DEL) screening.

Our expertise includes hit selection, prioritization, characterization, and optimization into high-affinity, receptor-selective peptide ligands.

For targeted radiotherapeutics, we focus on optimizing tumor targeting, cellular internalization, pharmacokinetics, and tissue distribution while minimizing uptake and retention in healthy organs.

Peptide-Based Radiotherapeutics Consulting

We specialized expertise in the discovery and optimization of peptide-based radiotherapeutics for targeted cancer treatment.

We support the selection and optimization of peptide targeting vectors, linkers, chelators, and radiolabeling strategies to achieve favorable tumor-to-normal tissue exposure ratios and maximize therapeutic potential.

By integrating peptide medicinal chemistry with expertise in radiopharmaceutical pharmacology and biodistribution, we help clients advance differentiated peptide-based radiotherapeutic candidates from initial discovery through preclinical evaluation.

Integrated Scientific Expertise

Peptide-Based Radiotherapeutics Consulting

Integrated Scientific Expertise

With more than 30 years of experience across the biotechnology and pharmaceutical industries, Ferdia Therapeutics brings specialized expertise in peptide medicinal chemistry, pharmacokinetic optimization, radiopharmaceutical pharmacology, and biodistribution.

We partner with clients to address complex scientific challenges, optimize promising candidates, and advance innovative peptide therapeutics toward their development goals.

Apelin Analogs

This project aims to develop a long-acting peptide suitable for once-weekly dosing for treatment of age-related loss of muscle mass and function. The lead candidate is in IND enabling studies with FIH planned for early 2027. The project is partnered with Vasa Therapeutics. www.vasatherapeutics.com